Lactose (India) Ltd
Incorporated in 1991, Lactose (India) Ltd manufactures Pharmaceutical Products and carries out job work[1]
- Market Cap ₹ 128 Cr.
- Current Price ₹ 101
- High / Low ₹ 137 / 76.0
- Stock P/E 21.1
- Book Value ₹ 51.5
- Dividend Yield 0.00 %
- ROCE 11.3 %
- ROE 9.81 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 34.8% CAGR over last 5 years
- Company's working capital requirements have reduced from 22.6 days to 18.1 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.3% over last 3 years.
- Promoters have pledged 26.1% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 163 | |
| 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 145 | |
| Operating Profit | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 18 |
| OPM % | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 11% |
| 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |
| Interest | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 5 |
| Depreciation | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 |
| Profit before tax | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 9 |
| Tax % | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | 30% |
| 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 6 | |
| EPS in Rs | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.10 | 4.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 36% |
| 3 Years: | 35% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 35% |
| 3 Years: | 72% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 24% |
| 3 Years: | 28% |
| 1 Year: | 2% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 | 52 |
| 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 | 62 | |
| 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 | 56 | |
| Total Liabilities | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 183 |
| 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 | 69 | |
| CWIP | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 | 114 | |
| Total Assets | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 183 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 | 1 | 8 | 0 | 5 | 7 | 2 | 8 | 8 | 9 | -0 | 6 | |
| -23 | 3 | -5 | -2 | -2 | -3 | -6 | -1 | -1 | -2 | -16 | -10 | |
| 10 | -5 | -3 | 4 | -5 | -4 | 5 | -8 | -8 | -6 | 19 | 1 | |
| Net Cash Flow | -1 | -0 | -0 | 3 | -2 | 1 | 1 | -0 | -1 | 1 | 3 | -4 |
| Free Cash Flow | -10 | -0 | 3 | -2 | 3 | 4 | -3 | 7 | 6 | 7 | -14 | -5 |
| CFO/OP | 255% | 18% | 74% | 15% | 58% | 80% | 34% | 68% | 70% | 50% | 5% | 37% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 | 75 |
| Inventory Days | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 | 217 |
| Days Payable | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 | 146 |
| Cash Conversion Cycle | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 | 146 |
| Working Capital Days | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 | 18 |
| ROCE % | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% | 11% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Consumption KWH |
|
|||||||||
| Foreign Exchange Earned (Export Revenue) Rs Lakh |
||||||||||
| Installed Capacity - Lactose Powder MTPA |
||||||||||
| Bio Coal Consumption MT |
||||||||||
| Employee Count count |
||||||||||
| Installed Capacity - Lactulose MTPA |
||||||||||
| Number of Registered Customers count |
||||||||||
| Order Book (Quarterly) Rs Crore |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
14 Jul - CRISIL reaffirmed Lactose's BBB-/Stable rating on enhanced Rs.90 crore bank facilities on 13 July 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jul - Pursuant to Regulation 74(5) of SEBI (DP) Regulation, 2018, we hereby submit the certificate issued by RTA.
- Closure of Trading Window 29 Jun
-
Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015 For Forfeiture Of Convertible Warrants
18 Jun - Board approved forfeiture of 15 lakh warrants; Rs 6.52 crore premium forfeited on 18 June 2026.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (LODR) Regulations, 2015.
15 Jun - Board meeting on 18 June 2026 to forfeit 15 lakh convertible share warrants.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
LIL, associated with the Kerry Group, is involved in the production of pharmaceuticals, drugs, medicines, chemicals, and food products. The company operates as a manufacturer, processor, exporter, importer, and distributor across multiple categories, including:
a) all types of food—finished, semi-finished, processed, and unprocessed;
b) dairy products such as milk cream, ice cream, curd, paneer, cheese, and sweets;
c) pharmaceuticals, bulk drugs, and medicines; and
d) chemicals, compounds, derivatives, and intermediates.